Exai Bio says novel RNA and AI-driven platform can detect early breast cancer
Exai Bio, a leader in healthcare innovation, announced groundbreaking data showcasing the efficacy of its novel RNA-based and AI-driven liquid biopsy platform in detecting breast cancer at its earliest stages. The platform’s precision in identifying small tumors, including ductal carcinoma in situ (DCIS), using a standard blood sample, marks a significant advancement in cancer screening. […]